MJA
MJA

Congenital cytomegalovirus — time to diagnosis, management and clinical sequelae in Australia: opportunities for earlier identification

Med J Aust 2011; 194 (12): 625-629.

Summary

Objectives: To report on the burden of disease in Australian infants with congenital cytomegalovirus (cCMV) infection in the era of neonatal hearing screening and improved diagnostic techniques.

Design, setting and participants: National data were collected from across Australia via the Australian Paediatric Surveillance Unit (APSU) with monthly reporting by > 1000 clinicians between January 1999 and February 2009. For each reported case, data on investigations and epidemiological and clinical features were analysed. Detailed clinical reviews were performed on 42 infants in two Sydney tertiary paediatric infectious diseases clinics.

Results: There were 195 infants with cCMV identified, including 126 definite and 69 probable cases. Of these, 175 (90%) were symptomatic and only 15 were treated with antiviral agents. Identification was delayed beyond 60 days of age in 30 cases (15%). During the period of study, neonatal hearing screening was introduced for most Australian infants. Detection of hearing loss increased from 19% of cCMV cases in 1999–2003 to 31% in 2004–2009. Of 42 infants whose cases were reviewed in detail, 33 (79%) had symptomatic disease. DNA detection of CMV, using polymerase chain reaction testing of newborn screening cards, was useful in retrospective identification, and was strongly correlated with the presence of clinical sequelae (15/18; 83%).

Conclusions: Congenital CMV is underdiagnosed, infrequently treated, and often manifests as isolated hearing loss. Delayed diagnoses both before and after the introduction of neonatal hearing screening represent missed treatment and management opportunities and are likely to lead to poorer, life-long outcomes for these children. Retrospective analysis of newborn screening cards for CMV should be undertaken for infants with sensorineural hearing loss, to identify unrecognised cCMV.

  • Brendan J McMullan1,2
  • Pamela Palasanthiran2,3
  • Cheryl A Jones4,5
  • Beverley M Hall6
  • Peter W Robertson6
  • Jonathan Howard7,2
  • William D Rawlinson6,2

  • 1 St Vincent’s Hospital, Sydney, NSW.
  • 2 University of New South Wales, Sydney, NSW.
  • 3 Sydney Children’s Hospital, Sydney, NSW.
  • 4 The Children’s Hospital at Westmead, Sydney, NSW.
  • 5 University of Sydney, Sydney, NSW.
  • 6 South Eastern Sydney and Illawarra Area Health Service, Sydney, NSW.
  • 7 Prince of Wales Hospital, Sydney, NSW.

Correspondence: w.rawlinson@unsw.edu.au

Acknowledgements: 

We thank Dr Lyndall Brennan for assistance with assay development, and the APSU and reporting doctors for their contributions. APSU activities are supported by the Department of Health and Ageing; a National Health and Medical Research Council Enabling Grant (No. 402784) and Practitioner Fellowship (No. 457084, E Elliott); Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney; the Children’s Hospital at Westmead, and the Royal Australasian College of Physicians.

Competing interests:

None identified.

  • 1. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-276.
  • 2. Zurynski Y, Cronin P, Elliott EJ. Communicable and vaccine-preventable conditions under surveillance by the APSU: 2004 update. Commun Dis Intell 2005; 29: 407-411.
  • 3. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17: 355–363.
  • 4. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 2005; 5: 70.
  • 5. Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. Pediatr 1997; 130: 624-630.
  • 6. Munro SC, Trincado D, Hall B, Rawlinson WD. Symptomatic infant characteristics of congenital cytomegalovirus disease in Australia. J Paediatr Child Health 2005; 41: 449-452.
  • 7. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143: 16-25.
  • 8. Howard J, Hall B, Brennan L, et al. Utility of newborn screening cards for detecting CMV infection in cases of stillbirth. J Clin Virol 2009; 44: 215-218.
  • 9. Barbi M, Binda S, Caroppo S, Primache V. Neonatal screening for congenital cytomegalovirus infection and hearing loss. J Clin Virol 2006; 35: 206-209.
  • 10. Munro SC, Hall B, Whybin LR, et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol 2005; 43: 4713-4718.
  • 11. Barbi M, Binda S, Primache V, et al. Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J Clin Virol 2000; 17: 159-165.
  • 12. McIver CJ, Jacques CF, Chow SS, et al. Development of multiplex PCRs for detection of common viral pathogens and agents of congenital infections. J Clin Microbiol 2005; 43: 5102-5110.
  • 13. Australian Bureau of Statistics. Births Australia, 2007. Canberra: ABS, 2008. (ABS Cat. No. 3301.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3301.02007 (accessed May 2011).
  • 14. Australian Bureau of Statistics. Perinatal deaths. Canberra: ABS, 2008. http://www.abs.gov.au/ausstats/abs@.nsf/mf/3304.0 (accessed May 2011).
  • 15. Boppana SB, Fowler KB, Vaid Y, et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics 1997; 99: 409-414.
  • 16. Australian Bureau of Statistics. 2008 Year Book Australia. Canberra: ABS, 2008. (ABS Cat. No. 1301.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/1301.02008?OpenDocument (accessed May 2011).
  • 17. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008; 197: 836-845.
  • 18. National Institute of Allergy and Infectious Diseases. Short-term vs. long-term valganciclovir therapy for symptomatic congenital CMV infections (CASG 112) [clinical trial]. http://clinicaltrials.gov/ct2/show/NCT00466817 (accessed May 2011).
  • 19. Australian National Hearing Screening Committee. Australian consensus statement on universal neonatal hearing screening. Melbourne: Royal Children’s Hospital, 2002. http://www.rch.org.au/emplibrary/ccch/Con sensusFinalApr2002.pdf (accessed May 2011).
  • 20. Wilson JM, Jungner YG. [Principles and practice of mass screening for disease] [Spanish]. Bol Oficina Sanit Panam 1968; 65: 281-393.
  • 21. Ludwig A, Hengel H. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill 2009; 14: 26-32.
  • 22. Forsgren M. Prevention of congenital and perinatal infections. Euro Surveill 2009; 14: 2-4.
  • 23. Vossen A, de Vries J, van der Zeijst B. The 2008 congenital cytomegalovirus conference, 5–7 November, Centers for Disease Control and Prevention, Atlanta. Euro Surveill 2009; 14: 1-2.
  • 24. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol 2008; 41: 57-62.
  • 25. Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol 2006; 35: 226-231.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article